Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make ...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy classified by WHO and marked by cutaneous lesions, bone marrow infiltration, and CNS involvement.

One Connecticut kid undergoing cancer treatment just received a huge gift, thanks to a Wilton nonprofit. Elijah Randolph, 13, ...

LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 ...

NoviThera ApS ("NoviThera"), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) ("Nordicus" or the "Company"), a financial ...

NoviThera ApS (“NoviThera”), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic ...

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), ...

This review outlines the emerging role of Interleukin-26 in autoimmune disease biology and describes a possible diagnostic and therapeutic signal for patient monitoring and future stratification.

“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” “Our ...

Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes. Detection of ...

Clinical studies have identified that reduced numbers of circulating plasmacytoid dendritic cells (pDCs) act as a predictor of cardiovascular events in coronary artery disease and that pDCs are ...